Lys332
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys332  -  STEAP1 (human)

Site Information
EDVTkINkTEICsQL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12247543

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
vorinostat ( 1 )

References 

1

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

2

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

3

Possemato A (2009) CST Curation Set: 8244; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

4

Possemato A (2009) CST Curation Set: 8247; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

5

Possemato A (2009) CST Curation Set: 8242; Year: 2010; Biosample/Treatment: cell line, LNCaP/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

6

Possemato A (2009) CST Curation Set: 8246; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

7

Possemato A (2009) CST Curation Set: 8243; Year: 2010; Biosample/Treatment: cell line, LNCaP/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

8

Possemato A (2009) CST Curation Set: 8245; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

9

Possemato A (2009) CST Curation Set: 8241; Year: 2010; Biosample/Treatment: cell line, LNCaP/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info